My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1044
    CAS #: 71125-38-7Purity ≥98%

    Description: Meloxicam (Parocin; Movicox; Meloxicamum; Mobic; Mobicox; reumoxicam; Movalis; Uticox), an approved medication used to treat pain and inflammation in rheumatic arthritis and osteoarthritis, is a potent non-steroidal anti-inflammatory drug (NSAID) which acts as a selective COX inhibitor with IC50s of 0.49 µM and 36.6 µM for COX-2 and COX-1, respectively. I is used to relieve pain and fever effects. Studies suggest that Meloxicam is Cox-2 preferential, therefore it will probably not display a lower gastrointestinal toxicity than non-selective anti-inflammatory agents. This compound has been shown to also inhibit prostanoid synthesis in inflammatory cells. It shows potent anti-inflammatory, antipyretic, and analgesic effects with low gastrointestinal toxicity in animal models. 

    References: Equine Vet J. 2009 Sep;41(7):693-9; Carcinogenesis. 2006 Mar;27(3):584-92; Carcinogenesis. 1998 Dec;19(12):2195-9.

    Related CAS#: 942047-63-4 (Meloxicam D4)

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)351.4
    CAS No.71125-38-7
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 30 mg/mL (85.4 mM)
    Water:<1 mg/mL
    Ethanol:<1 mg/mL
    Other info

    Chemical Name: (E)-3-(hydroxy((5-methylthiazol-2-yl)amino)methylene)-2-methyl-2H-benzo[e][1,2]thiazin-4(3H)-one 1,1-dioxide


    InChi Code: InChI=1S/C14H13N3O4S2/c1-8-7-15-14(22-8)16-13(19)11-12(18)9-5-3-4-6-10(9)23(20,21)17(11)2/h3-7,19H,1-2H3,(H,15,16)/b13-11+

    SMILES: CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O


    Parocin; reumoxicam; Movicox; Mobic; Mobicox; Movalis; Meloxicamum; Uticox; 

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity:  Meloxicam significantly reduces HCA-7 and Moser-S colony size. Meloxicam significantly inhibits HCA-7 colony and tumor growth but has no effect on the growth of the COX-2 negative HCT-116 cells. Meloxicam inhibits PGE(2) production, proliferation and invasiveness especially in MG-63 cells, which express relatively high levels of COX-2. Meloxicam causes apoptosis and upregulates Bax mRNA and protein in MG-63 cell culture.

    Cell Assay: CF41.Mg and MDCK cells are seeded at a density of 1.5 × 103 cells/well into 96-well plates, cultured for 24 h and then exposed to 0-25 µg/mL Meloxicam alone or in combination with doxorubicin. To evaluate synergism and sensitization, doxorubicin is added at the same time and after 24 h, respectively. MDCK cells are exposed only to Meloxicam as a non-tumor negative control. Control groups are cultured without Meloxicam and doxorubicin, but the corresponding amount of DMSO is added to the medium. Following an incubation period of 24 and 48 h, cell growth is measured using the MTS assay, with the absorbance at 490 nm determined using a microplate reader. Each experiment is performed 3 times in triplicate.

    In VivoMeloxicam suppresses LM-8 tumor growth and lung metastasis in vivo mouse model. Meloxicam causes a significant reduction in lameness at post injection hour (PIH) 8 and 24 and tends to reduce effusion in horse. Meloxicam significantly suppresses synovial fluid (SF) prostaglandin E2 and substance P release at PIH 8 and bradykinin at PIH 24 compared to placebo treatment in horse. Meloxicam reduces general MMP activity at PIH 8 and 24 in horse. Meloxicam- or flunixin-treated horses has improved postoperative pain scores and clinical variables, compared with SS-treated horses. Meloxicam results in high numbers of neutrophils in ischemia-injured tissue of horse. Meloxicam administration significantly suppresses PGE2 concentrations in blood and synovial fluid at days 7 and 21, but has no effect on concentrations of TXB2 in blood or PGE2 in gastric mucosa in dogs.
    Animal modelMice, horse, and dogs
    Formulation & DosageN/A

    Carcinogenesis. 1998 Dec;19(12):2195-9;  Equine Vet J. 2009 Sep;41(7):693-9; Carcinogenesis. 2006 Mar;27(3):584-92; Am J Vet Res. 2007 Jun;68(6):614-24.

    These protocols are for reference only. InvivoChem does not independently validate these methods.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?